- ￥1600 - 2650
- MultiSciences
- 15.63 pg/mL - 1000 pg/mL
- 杭州
- EK1236
- 2025年12月10日
企业认证
研选同类产品更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 用户评价
- 文献和实验
- 技术资料
- 库存：
99
- 供应商：
联科生物
- 检测范围：
15.63 pg/mL - 1000 pg/mL
- 检测方法：
双抗夹心法
- 应用：
ELISA
- 适应物种：
Human
- 标记物：
HRP
- 样本：
血清，血浆，细胞培养上清及其他生物学样本
- 规格：
96T/48T
| 规格： | 96T | 产品价格： | ￥2650.0 |
|---|---|---|---|
| 规格： | 48T | 产品价格： | ￥1600.0 |
| 背景介绍 | 干扰素(IFNs)是宿主细胞在响应病原体(如病毒、细菌、寄生虫或者肿瘤细胞)时合成和释放的一组信号蛋白。在通常情况下，病毒感染的细胞会释放干扰素，使周围的细胞提高其抗病毒防御能力。基于受体类型，人类干扰素可分为3大类型：I型干扰素，包括IFN-α、IFN-β、IFN-ε、IFN-κ和IFN-ω，II型干扰素(在人类中称为IFN-γ)和III型干扰素。
IFN-β通过信号通路STAT1和STAT2上调和下调多种基因，其中，大部分基因参与抗病毒免疫反应。IFN-β在诱导广泛的非特异性抗病毒感染中起重要作用，它还影响细胞增殖并调节免疫应答。 |
| 检测原理 | 本试剂盒采用双抗体夹心酶联免疫吸附检测技术。特异性抗人IFN-β抗体预包被在高亲和力的酶标板上。酶标板孔中加入标准品、待测样本和生物素化的检测抗体，经过孵育，样本中存在的IFN-β与固相抗体和检测抗体结合。洗涤去除未结合的物质后，加入辣根过氧化物酶标记的链霉亲和素(Streptavidin-HRP)。洗涤后，加入显色底物TMB，避光显色。颜色反应的深浅与样本中IFN-β的浓度成正比。加入终止液终止反应，在450 nm波长(参考波长570-630 nm)测定吸光度值。 |
| 组分 | 包被抗IFN-β单克隆抗体的96孔聚苯乙烯酶标板 人IFN-β冻干标准品 IFN-β检测抗体 标准品稀释液 检测缓冲液(10×) 底物(TMB) 终止液 洗液(20×) 封板膜 |
| 分析类型 | 夹心ELISA |
| 样本类型 | 血清、血浆，细胞培养上清及其他生物学样本 |
| 板式 | 96孔板，可拆 |
| 保存 | 试剂盒未拆开，4℃保存。已拆开，标准品-20℃保存，其它4℃保存。 |
| 运输条件 | 4℃蓝冰运输 |
| 样本体积 | 50μl |
| 灵敏度 | 3.19 pg/ml |
| 标曲图 |  |
| 标准曲线范围 | 15.63-1000 pg/ml |
| 回收率范围 | 79 %-95 % |
| 平均回收率 | 0.88 |
| 板间变异系数 | 3.6 %-7.9 % |
| 板内变异系数 | 4.5 %-5.0 % |
概述人 IFNB1, IFN-β, IFNB 靶点信息
IFNB1 分子靶点信息概述
- 分子名：IFNB1, interferon beta 1
- 基因家族：Interferons
- 别名：IFB; IFF
- 曾用名：IFNB
- 全称：interferon, beta 1, fibroblast
IFNB1 分子靶点综述
干扰素(IFNs)是宿主细胞在响应病原体(如病毒、细菌、寄生虫或者肿瘤细胞)时合成和释放的一组信号蛋白。在通常情况下，病毒感染的细胞会释放干扰素，使周围的细胞提高其抗病毒防御能力。基于受体类型，人类干扰素可分为3大类型：I型干扰素，包括IFN-α、IFN-β、IFN-ε、IFN-κ和IFN-ω，II型干扰素(在人类中称为IFN-γ)和III型干扰素。IFN-β通过信号通路STAT1和STAT2上调和下调多种基因，其中，大部分基因参与抗病毒免疫反应。IFN-β在诱导广泛的非特异性抗病毒感染中起重要作用，它还影响细胞增殖并调节免疫应答。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
用户评价
暂无用户评价
文献和实验- IF = 32.086 Herpesvirus-Mimicking DNAzyme-Loaded Nanoparticles As a Mitochondrial DNA Stress Inducer to Activate Innate Immunity for Tumor Therapy. ADVANCED MATERIALS (2022)
- IF = 16.744 In-situ self-assembled vaccine constructed with dual switchable nanotransformer for tumor immunotherapy. CHEMICAL ENGINEERING JOURNAL (2022)
- IF = 15.304 Activating cGAS-STING pathway with ROS-responsive nanoparticles delivering a hybrid prodrug for enhanced chemo-immunotherapy. BIOMATERIALS (2022)
- IF = 15.304 Regulating T-cell metabolic reprogramming and blocking PD-1 co-promote personalized postoperative autologous nanovaccines. BIOMATERIALS (2023)
- IF = 13.273 Simultaneous innate immunity activation and immunosuppression improvement by biodegradable nanoplatform for boosting antitumor chemo-immunotherapy. CHEMICAL ENGINEERING JOURNAL (2022)
- IF = 12.701 SHP2-Mediated Inhibition of DNA Repair Contributes to cGAS–STING Activation and Chemotherapeutic Sensitivity in Colon Cancer. CANCER RESEARCH (2021)
- IF = 11.614 Allosteric inhibition reveals SHP2-mediated tumor immunosuppression in colon cancer by single-cell transcriptomics. Acta Pharmaceutica Sinica B (2021)
- IF = 10.7 Gut microbial GABAergic signaling improves stress-associated innate immunity to respiratory viral infection. Journal of Advanced Research (2023)
- IF = 10.633 Integrated manganese (III)-doped nanosystem for optimizing photothermal ablation: Amplifying hyperthermia-induced STING pathway and enhancing antitumor immunity. Acta Biomaterialia (2022)
- IF = 10.633 Multifunctional biomimetic nanoplatform based on photodynamic therapy and DNA repair intervention for synergistic treatment of breast cancer. Acta Biomaterialia (2022)
- IF = 10.334 Oroxylin A regulates cGAS DNA hypermethylation induced by methionine metabolism to promote HSC senescence. PHARMACOLOGICAL RESEARCH (2022)
- IF = 7.561 PreS/2-21-Guided siRNA Nanoparticles Target to Inhibit Hepatitis B Virus Infection and Replication.. Frontiers in Immunology (2022)
- IF = 6.107 Irradiation combined with PD-L1−/− and autophagy inhibition enhances the antitumor effect of lung cancer via cGAS-STING-mediated T cell activation. iScience (2022)
- IF = 5.811 Tanreqing Inhibits LPS-Induced Acute Lung Injury In Vivo and In Vitro Through Downregulating STING Signaling Pathway. Frontiers in Pharmacology (2021)
- IF = 5.192 Toxoplasma gondii ROP18I inhibits host innate immunity through cGAS-STING signaling. FASEB JOURNAL (2022)
- IF = 4.939 Efficient Delivery of Chlorin e6 by Polyglycerol-Coated Iron Oxide Nanoparticles with Conjugated Doxorubicin for Enhanced Photodynamic Therapy of Melanoma. MOLECULAR PHARMACEUTICS (2021)
- IF = 4.553 Harnessing chlorin e6 loaded by functionalized iron oxide nanoparticles linked with glucose for target photodynamic therapy and improving of the immunogenicity of lung cancer. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)
- IF = 4.36 Anti-influenza A virus mechanism of three representative compounds from Flos Trollii via TLRs signaling pathways. JOURNAL OF ETHNOPHARMACOLOGY (2020)
- IF = 4.219 NLRP3 protects mice from radiation-induced colon and skin damage via attenuating cGAS-STING signaling. TOXICOLOGY AND APPLIED PHARMACOLOGY (2021)
- IF = 4.162 A Network Pharmacology-Based Investigation to the Pharmacodynamic Material Basis and Mechanisms of the Anti-Inflammatory and Anti-Viral Effect of Isatis indigotica. Drug Design Development and Therapy (2021)
consists of a cooperation between monocytes and cytophilic antibodies able to bind to the Fc receptors present on the monocyte surface. Thus human IgG1 and IgG3 are the main isotypes effective in ADCI, whereas IgG2, IgG4, and IgM are ineffective
Human Xanthine Oxidoreductase Determination by a Competitive ELISA
Xanthine oxidoreductase (XO) catalyses the oxidation of hypoxanthine to xanthine and of the latter to uric acid. The enzyme is present in traces in most of human tissues, including plasma, being more abundant in milk, liver, and intestine (1).
ELISA原理与实验方法The advantages of the ELISA are similar to other antibody-labeled reactions which include specificity, sensitivity, inexpensiveness, and safety. Since the enzyme label is the critical portion of ELISA, its selection is very important
技术资料需要更多技术资料 索取更多技术资料
